Research Paper Volume 15, Issue 11 pp 5032—5051
CLDN5 identified as a biomarker for metastasis and immune infiltration in gastric cancer via pan-cancer analysis
Figure 10. CLDN5 staining in gastric adenocarcinoma tissue microarrays using immunohistochemical methods. (A) CLDN5 is highly expressed in the para cancer and decreases with change in the pathological stage. (B) Relative expression of CLDN5 in 78 pairs of STAD and para-cancerous tissues (p < 0.001). (C) Relationship between CLDN5 expression and clinical stage, CLDN5 was elevated in clinical stage II, consistent with TCGA results. (D) CLDN5 expression in GSE49051 datasets, CLDN5 expression was decreased in normal than STAD (p <0.05). (E–G) Validation of CLDN5 expression in GEO datasets and ROC curves analysis. (E) CLDN5 expression in GSE64951 datasets, CLDN5 expression was decreased in normal salivary than STAD salivary (p <0.05). (F) The TCGA training result. The AUC values were 0.733. (G) The GEO test sets results. The AUC values were 0.659.